|
Prevention of Dichloroacetate Toxicity Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Prevention of Dichloroacetate Toxicity conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Prevention of Dichloroacetate Toxicity Clinical research trials and Prevention of Dichloroacetate Toxicity health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Prevention of Dichloroacetate Toxicity. Prevention of Dichloroacetate Toxicity Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Prevention of Dichloroacetate Toxicity clinical trial. Participants oftentimes recieve the most expert healthcare available for their Prevention of Dichloroacetate Toxicity condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Prevention of Dichloroacetate Toxicity  Prevention of Dichloroacetate Toxicity
Prevention of Dichloroacetate Toxicity
For Condition: Acidosis, Lactic,Chronic Disease
Status: Recruiting
Sponsor(s): FDA Office of Orphan Products Development ,
Synopsis: This is a study to determine the safety of dichloroacetate (DCA) with a low-tyrosine diet given with or without nitisinone (NTBC) in children with chronic lactic acidosis (CLA).
Details: DCA is being studied for the treatment of patients with CLA, which is a rare collection of mitochondrial metabolism errors causing cellular energy failure and early death. DCA causes reversible liver and peripheral nerve toxicity and it interrupts both tyrosine and heme metabolism. The inhibitory effect of DCA on mammalian tyrosine metabolism elicits biochemical changes similar to those observed in hereditary tyrosinemia type I (HT). However, some reports and studies indicate substantial reduction in the biochemical and clinical consequences of HT may occur when patients are treated concomitantly with a low-tyrosine diet (LTD) and the chemical NTBC, which inhibits an early step in tyrosine catabolism. Possibly, the same dietary and pharmacologic interventions may mitigate or prevent toxicity associated with chronic DCA exposure. Patients visit the Center 5 times over a 1-year period, usually for 2 to 3 days per visit, for an extensive series of clinical and biochemical tests. Visit 1 is for baseline examinations and blood and urine chemistries and to educate the patient on an LTD. This visit lasts approximately 7 days to determine acceptable circulating tyrosine concentrations for LTD formula at discharge. Patients are provided with tubes to take to local laboratories every 2 weeks for blood work. Patients are readmitted in 1 month to determine adherence to diet and serum tyrosine levels. Patients who evidence dietary compliance, no adverse effects, and a willingness to continue are placed in 1 of 2 treatment arms: DCA plus an LTD plus placebo or DCA plus an LTD plus NTBC. Thereafter, patients return during Months 5, 9, and 13, which completes their 1-year treatment phase.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study
Minimum Age/Maximum Age: 3 Months/21 Years
Genders: Both
Protocol Entry Criteria: Inclusion criteria: - Biochemical or molecular genetic proof of a defect in mitochondrial enzyme of glucose metabolism or oxidative phosphorylation. - Clinical history consistent with CLA (e.g., basal hyperlactatemia, stroke-like episodes, neuromuscular degeneration, and seizures). - Ability to withstand an 8-hour fast (if 2 years old or younger) or a 12-hour fast without developing hypoglycemia (blood glucose greater than or equal to 50 mg/dL). Exclusion criteria: - Secondary lactic acidosis due to impaired oxygenation or circulation. - Hyperlactatemia associated with proven biotinidase deficiency or with enzyme deficiencies of gluconeogenesis. - Primary, defined organic acidurias other than lactic acidosis for which effective therapy is available (e.g., propionic aciduria). - Primary disorders of amino acid metabolism. - Primary disorders of fatty acid oxidation. - Malabsorption syndromes associated with D-lactic acidosis. - Renal insufficiency. - Serum creatinine greater than 1.2 mg/g. - Creatinine clearance less than or equal to 60 mL/min. - Primary hepatic disease unrelated to chronic lactic acidosis. - In patients with pyruvate dehydrogenase enzyme complex deficiency, an inability to maintain a diet greater than 50% calories from fat without biological and/or neurological deterioration.
Total Enrollment: 30
Location and Contact Information:
University of Florida *Recruiting*
Gainesville, Florida, 32610
United States
Recruiting Peter Stacpoole 352-392-2321
Additional Information:
Study ID Numbers: FD-R-2013-01; FD-R-002013-01
Study Start Date: September 2001
Record last reviewed: January 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00031161
Other Acidosis, Lactic Studies:
1. Prevention of Dichloroacetate Toxicity
2. Evaluation of Lyme Disease: Clinical, Microbiological and Immunological Characteristics
3. Nurse Counseling for Physical Activity in Primary Care Patients
Related Studies:
Other Acidosis, Lactic Clinical Trials
Other Florida Clinical Trials
Other Gainesville Clinical Trials
Prevention of Dichloroacetate Toxicity
|
|
|
|
|
|
|
|
